# CS Disco, Inc.: financial statements, quarterly

LAW · NYSE · CIK 1625641 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/law.md) · [Financials](/companies/law/financials.md) · [Filings](/companies/law/filings.md) · [Insiders](/companies/law/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/law/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [34.9](/filings/0001625641-24-000154.md) | [35.7 d](/filings/0001625641-25-000027.md) | [35.6](/filings/0001625641-25-000070.md) | [36.0](/filings/0001625641-25-000120.md) | [36.3](/filings/0001625641-25-000172.md) | [37.0 d](/filings/0001625641-26-000044.md) | [36.7](/filings/0001625641-26-000108.md) | [38.1](/filings/0001625641-26-000162.md) | [40.9](/filings/0001625641-25-000172.md) | [41.2 d](/filings/0001625641-26-000044.md) | [41.9](/filings/0001625641-26-000108.md) | [43.1](/filings/0001625641-26-000162.md) |
| Cost of revenue | $m | [8.9](/filings/0001625641-24-000154.md) | [8.7 d](/filings/0001625641-25-000027.md) | [8.9](/filings/0001625641-25-000070.md) | [9.3](/filings/0001625641-25-000120.md) | [9.7](/filings/0001625641-25-000172.md) | [9.5 d](/filings/0001625641-26-000044.md) | [9.5](/filings/0001625641-26-000108.md) | [9.7](/filings/0001625641-26-000162.md) | [10.0](/filings/0001625641-25-000172.md) | [10.2 d](/filings/0001625641-26-000044.md) | [10.8](/filings/0001625641-26-000108.md) | [11.0](/filings/0001625641-26-000162.md) |
| Gross profit | $m | [26.0](/filings/0001625641-24-000154.md) | [27.0 d](/filings/0001625641-25-000027.md) | [26.7](/filings/0001625641-25-000070.md) | [26.7](/filings/0001625641-25-000120.md) | [26.5](/filings/0001625641-25-000172.md) | [27.5 d](/filings/0001625641-26-000044.md) | [27.2](/filings/0001625641-26-000108.md) | [28.4](/filings/0001625641-26-000162.md) | [30.9](/filings/0001625641-25-000172.md) | [30.9 d](/filings/0001625641-26-000044.md) | [31.1](/filings/0001625641-26-000108.md) | [32.1](/filings/0001625641-26-000162.md) |
| Research and development | $m | [12.1](/filings/0001625641-24-000154.md) | [10.5 d](/filings/0001625641-25-000027.md) | [12.1](/filings/0001625641-25-000070.md) | [12.9](/filings/0001625641-25-000120.md) | [12.8](/filings/0001625641-25-000172.md) | [13.8 d](/filings/0001625641-26-000044.md) | [14.3](/filings/0001625641-26-000108.md) | [14.0](/filings/0001625641-26-000162.md) | [13.4](/filings/0001625641-25-000172.md) | [15.0 d](/filings/0001625641-26-000044.md) | [14.7](/filings/0001625641-26-000108.md) | [14.9](/filings/0001625641-26-000162.md) |
| Operating income | $m | [(2.9)](/filings/0001625641-24-000154.md) | [(7.7) d](/filings/0001625641-25-000027.md) | [(12.3)](/filings/0001625641-25-000070.md) | [(12.4)](/filings/0001625641-25-000120.md) | [(10.9)](/filings/0001625641-25-000172.md) | [(26.1) d](/filings/0001625641-26-000044.md) | [(12.6)](/filings/0001625641-26-000108.md) | [(11.8)](/filings/0001625641-26-000162.md) | [(14.5)](/filings/0001625641-25-000172.md) | [(9.2) d](/filings/0001625641-26-000044.md) | [(10.1)](/filings/0001625641-26-000108.md) | [(9.2)](/filings/0001625641-26-000162.md) |
| Income tax | $m | [0.1](/filings/0001625641-24-000154.md) | [0.3 d](/filings/0001625641-25-000027.md) | [0.1](/filings/0001625641-25-000070.md) | [0.1](/filings/0001625641-25-000120.md) | [0.1](/filings/0001625641-25-000172.md) | [0.0 d](/filings/0001625641-26-000044.md) | [0.1](/filings/0001625641-26-000108.md) | [0.2](/filings/0001625641-26-000162.md) | [0.1](/filings/0001625641-25-000172.md) | [0.3 d](/filings/0001625641-26-000044.md) | [0.1](/filings/0001625641-26-000108.md) | [0.1](/filings/0001625641-26-000162.md) |
| Net income | $m | [(1.0)](/filings/0001625641-24-000154.md) | [(5.8) d](/filings/0001625641-25-000027.md) | [(10.6)](/filings/0001625641-25-000172.md) | [(10.8)](/filings/0001625641-25-000172.md) | [(9.2)](/filings/0001625641-25-000172.md) | [(25.2) d](/filings/0001625641-26-000044.md) | [(11.4)](/filings/0001625641-26-000162.md) | [(10.8)](/filings/0001625641-26-000162.md) | [(13.7)](/filings/0001625641-25-000172.md) | [(8.5) d](/filings/0001625641-26-000044.md) | [(9.6)](/filings/0001625641-26-000162.md) | [(8.7)](/filings/0001625641-26-000162.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0001625641-24-000154.md) | not reported | [(0.17)](/filings/0001625641-25-000070.md) | [(0.18)](/filings/0001625641-25-000120.md) | [(0.15)](/filings/0001625641-25-000172.md) | not reported | [(0.19)](/filings/0001625641-26-000108.md) | [(0.18)](/filings/0001625641-26-000162.md) | [(0.22)](/filings/0001625641-25-000172.md) | not reported | [(0.15)](/filings/0001625641-26-000108.md) | [(0.13)](/filings/0001625641-26-000162.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0001625641-24-000154.md) | not reported | [(0.17)](/filings/0001625641-25-000070.md) | [(0.18)](/filings/0001625641-25-000120.md) | [(0.15)](/filings/0001625641-25-000172.md) | not reported | [(0.19)](/filings/0001625641-26-000108.md) | [(0.18)](/filings/0001625641-26-000162.md) | [(0.22)](/filings/0001625641-25-000172.md) | not reported | [(0.15)](/filings/0001625641-26-000108.md) | [(0.13)](/filings/0001625641-26-000162.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [158](/filings/0001625641-23-000118.md) | [160](/filings/0001625641-25-000027.md) | [149](/filings/0001625641-24-000072.md) | [130](/filings/0001625641-24-000122.md) | [76.5](/filings/0001625641-24-000154.md) | [52.8](/filings/0001625641-26-000044.md) | [34.5](/filings/0001625641-25-000070.md) | [21.7](/filings/0001625641-25-000120.md) | [28.8](/filings/0001625641-25-000172.md) | [19.7](/filings/0001625641-26-000162.md) | [17.6](/filings/0001625641-26-000108.md) | [10.9](/filings/0001625641-26-000162.md) |
| Current assets | $m | [191](/filings/0001625641-23-000118.md) | [192](/filings/0001625641-25-000027.md) | [179](/filings/0001625641-24-000072.md) | [160](/filings/0001625641-24-000122.md) | [157](/filings/0001625641-24-000154.md) | [157](/filings/0001625641-26-000044.md) | [146](/filings/0001625641-25-000070.md) | [143](/filings/0001625641-25-000120.md) | [153](/filings/0001625641-25-000172.md) | [153](/filings/0001625641-26-000162.md) | [143](/filings/0001625641-26-000108.md) | [142](/filings/0001625641-26-000162.md) |
| Total assets | $m | [230](/filings/0001625641-23-000118.md) | [232](/filings/0001625641-25-000027.md) | [217](/filings/0001625641-24-000072.md) | [198](/filings/0001625641-24-000122.md) | [194](/filings/0001625641-24-000154.md) | [180](/filings/0001625641-26-000044.md) | [168](/filings/0001625641-25-000070.md) | [165](/filings/0001625641-25-000120.md) | [175](/filings/0001625641-25-000172.md) | [174](/filings/0001625641-26-000162.md) | [162](/filings/0001625641-26-000108.md) | [161](/filings/0001625641-26-000162.md) |
| Current liabilities | $m | [21.1](/filings/0001625641-23-000118.md) | [23.1](/filings/0001625641-25-000027.md) | [17.0](/filings/0001625641-24-000072.md) | [20.5](/filings/0001625641-24-000122.md) | [21.0](/filings/0001625641-24-000154.md) | [25.7](/filings/0001625641-26-000044.md) | [19.4](/filings/0001625641-25-000070.md) | [21.2](/filings/0001625641-25-000120.md) | [39.0](/filings/0001625641-25-000172.md) | [40.4](/filings/0001625641-26-000162.md) | [34.0](/filings/0001625641-26-000108.md) | [37.5](/filings/0001625641-26-000162.md) |
| Total liabilities | $m | [29.2](/filings/0001625641-23-000118.md) | [31.2](/filings/0001625641-25-000027.md) | [24.1](/filings/0001625641-24-000072.md) | [27.1](/filings/0001625641-24-000122.md) | [27.1](/filings/0001625641-24-000154.md) | [32.8](/filings/0001625641-26-000044.md) | [25.9](/filings/0001625641-25-000070.md) | [27.0](/filings/0001625641-25-000120.md) | [44.1](/filings/0001625641-25-000172.md) | [45.5](/filings/0001625641-26-000162.md) | [38.4](/filings/0001625641-26-000108.md) | [41.2](/filings/0001625641-26-000162.md) |
| Shareholders' equity | $m | [201](/filings/0001625641-24-000154.md) | [200](/filings/0001625641-26-000044.md) | [193](/filings/0001625641-25-000172.md) | [171](/filings/0001625641-25-000172.md) | [167](/filings/0001625641-25-000172.md) | [148](/filings/0001625641-26-000162.md) | [142](/filings/0001625641-26-000162.md) | [138](/filings/0001625641-26-000162.md) | [131](/filings/0001625641-25-000172.md) | [128](/filings/0001625641-26-000162.md) | [124](/filings/0001625641-26-000162.md) | [120](/filings/0001625641-26-000162.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.9) d](/filings/0001625641-24-000154.md) | [3.2 d](/filings/0001625641-25-000027.md) | [(7.3)](/filings/0001625641-25-000070.md) | [(0.7) d](/filings/0001625641-25-000120.md) | [(2.9) d](/filings/0001625641-25-000172.md) | [2.1 d](/filings/0001625641-26-000044.md) | [(10.5)](/filings/0001625641-26-000108.md) | [(4.2) d](/filings/0001625641-26-000162.md) | [(1.0) d](/filings/0001625641-25-000172.md) | [0.8 d](/filings/0001625641-26-000044.md) | [(11.7)](/filings/0001625641-26-000108.md) | [(1.1) d](/filings/0001625641-26-000162.md) |
| Capital expenditure | $m | [1.1 d](/filings/0001625641-24-000154.md) | [1.3 d](/filings/0001625641-25-000027.md) | [0.7](/filings/0001625641-25-000070.md) | [0.7 d](/filings/0001625641-25-000120.md) | [0.9 d](/filings/0001625641-25-000172.md) | [0.6 d](/filings/0001625641-26-000044.md) | [0.5](/filings/0001625641-26-000108.md) | [1.0 d](/filings/0001625641-26-000162.md) | [1.1 d](/filings/0001625641-25-000172.md) | [0.5 d](/filings/0001625641-26-000044.md) | [0.7](/filings/0001625641-26-000108.md) | [1.2 d](/filings/0001625641-26-000162.md) |
| Share repurchases | $m | [0.0 d](/filings/0001625641-24-000154.md) | [0.0 d](/filings/0001625641-25-000027.md) | [0.0](/filings/0001625641-25-000070.md) | [0.0 d](/filings/0001625641-25-000120.md) | [0.0 d](/filings/0001625641-25-000172.md) | [0.0 d](/filings/0001625641-26-000044.md) | [0.0](/filings/0001625641-26-000108.md) | [0.0 d](/filings/0001625641-26-000162.md) | [0.0 d](/filings/0001625641-25-000172.md) | [0.0 d](/filings/0001625641-26-000044.md) | [0.1](/filings/0001625641-26-000108.md) | [0.2 d](/filings/0001625641-26-000162.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [58.6](/filings/0001625641-23-000118.md) | [59.4](/filings/0001625641-24-000072.md) | [59.9](/filings/0001625641-24-000122.md) | [60.4](/filings/0001625641-24-000154.md) | [61.2](/filings/0001625641-25-000070.md) | [59.8](/filings/0001625641-25-000120.md) | [59.7](/filings/0001625641-25-000172.md) | [60.6](/filings/0001625641-26-000108.md) | [61.2](/filings/0001625641-26-000162.md) | [62.1](/filings/0001625641-25-000172.md) | [63.7](/filings/0001625641-26-000108.md) | [64.5](/filings/0001625641-26-000162.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 64,919,765 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001625641-26-000162.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.